Experts at ASGCT Ponder How Payment Models May Evolve With Market Entrance of Costly Gene Therapies
Regulators, economists, and drugmakers discussed how the healthcare system can manage under the growing pressure of gene therapies with multimillion-dollar price tags.
Guardant Health Secures New Commercial Payor Coverage for Liquid Biopsy Cancer Profiling Test
With new coverage from Anthem Blue Cross and Blue Shield, Aetna, and Humana, the firm's Guardant360/Guardant360 CDx assay is now covered by all major commercial health insurers.
UnitedHealthcare to Cover Whole-Genome Sequencing for Certain Non-Cancer Indications
The private payor published new coverage criteria for whole-genome sequencing tests for patients with a variety of non-cancer indications.
Invitae's PCM Assay for Minimal Residual Disease Detection Nabs Coverage by Blue Shield of California
The company's tests are now covered for cancer patients being assessed post-surgery or monitored for recurrence under a recent policy update.
Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana
Blue Shield of California and Blue Cross and Blue Shield of Louisiana are each covering Signatera for multiple cancer indications.